98%
921
2 minutes
20
One of the most complex human physiological processes to study is pregnancy. Standard animal models, as well as two-dimensional models, lack the complexity and biological relevance required to accurately study such a physiological process. Recent studies have focused on the development of three-dimensional models based on microfluidic systems, designated as placental microphysiological systems (PMPSs). PMPS devices provide a model of the placental barrier through culturing relevant cell types in specific arrangements and media to mimic the environment of the maternal-fetal circulation. Here, recent developments of PMPS models for embryo uterine implantation, preeclampsia evaluation, and toxicological screening are presented. Studies that use bioprinting techniques are also discussed. Lastly, recent developments in endometrium microphysiological systems are reviewed. All these presented models showed their superiority compared to standard models in recapitulating the biological environment seen . However, several limitations regarding the types of cells and materials used for these systems were also widely reported. Despite the need for further improvements, PMPS models contribute to a better understanding of the biological mechanisms surrounding pregnancy and the respective pathologies.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1039/d4lc00500g | DOI Listing |
Adv Drug Deliv Rev
September 2025
J. Crayton Pruitt Family Department of Biomedical Engineering, University of Florida, Gainesville, FL, United States; Emerging Pathogens Institute, University of Florida, Gainesville, FL, United States. Electronic address:
The human microbiome plays a critical role in health and disease. Disruptions in microbiota composition or function have been implicated not only as markers but also as drivers of diverse pathologies, creating opportunities for targeted microbiome interventions. Advancing these therapies requires experimental models that can unravel the complex, bidirectional interactions between human tissue and microbial communities.
View Article and Find Full Text PDFJ Mater Chem B
September 2025
Division of Pharmacology, Department of Pharmaceutical Sciences and Technology, Birla Institute of Technology, BIT Mesra Rd, Ranchi, Mesra, Jharkhand 835215, India.
Additive manufacturing (AM) has emerged as a transformative technology in personalized healthcare, particularly through its applications in targeted drug delivery and the development of microphysiological systems, potentiating a paradigm shift in healthcare towards a personalized intervention. This article explores how AM techniques, such as 3D printing, enable the creation of highly customized drug delivery systems and complex microphysiological models that can be translated into personalized healthcare solutions. By leveraging the precision and versatility of A, researchers and clinicians can design drug delivery vehicles attuned to patient needs, enhancing therapeutic efficacy and minimizing side effects.
View Article and Find Full Text PDFArch Toxicol
September 2025
National Institutes for Food and Drug Control, Beijing, 100050, China.
Traditional toxicological paradigms, reliant on animal testing and simplistic in vitro models, face significant limitations, including prolonged timelines, high costs, and poor translational predictability due to interspecies differences. This review highlights the transformative potential of New Approach Methodologies (NAMs) in overcoming these challenges. Key advancements include Organ-on-a-Chip (OoC) platforms that emulate human organ physiology and multi-organ crosstalk, significantly improving predictive accuracy.
View Article and Find Full Text PDFClin Pharmacol Ther
September 2025
Division of Translation and Clinical Pharmacology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
The shift from animal models to new approach methodologies (NAMs) in drug development requires experimental models that accurately reflect human biology. Characterizing protein abundance and composition in NAMs like microphysiological systems (MPS), enabling comparison with human tissues, allows identification of physiological differences, development of scaling factors for in silico models, monitoring of biomarkers, cellular heterogeneity, and interindividual variability. Thus, characterization of NAMs by quantitative proteomics is important for enhancing their translational and regulatory relevance.
View Article and Find Full Text PDFSensors (Basel)
August 2025
Departments of Biomedical Engineering and Dermatology, University of Rochester, Rochester, NY 14627, USA.
Tissue chips (TCs), otherwise known as organs-on-a-chip (OoC), organ chips (OCs), or microphysiological systems (MPS), are rapidly gaining prominence as an extension of or even replacement for traditional animal models of disease physiology. They also have recognized utility in the context of drug development: for example, data from TCs can now be submitted in place of some animal testing to the FDA. In principle, TCs are structured to allow measurement of any number of outputs that yield information about the tissue.
View Article and Find Full Text PDF